I bought more Paion
I am convinced that my research on the drug, and the fact that there was no excessive bleeding during the trial, which I consider the main risk, leads me to believe that the safety signal, whatever that may be, will be able to be overcome by the strength of the reperfusion that takes place when the drug is used.
Just my opinion. I have done a lot of work in this area.
the reason I believe that the clinical hold was not caused by excessive bleeding was because the DMB and the company would have know about bleeding as an SAE prior to the planned DSMB meeting.
